ATyr Pharma Analyst Ratings
ATyr Pharma Price Target Maintained With a $35.00/Share by HC Wainwright & Co.
ATyr Pharma Analyst Ratings
Buy Rating Affirmed: ATyr Pharma's Positive Clinical Developments and Strategic Expansion
ATyr Pharma Buy Rating: Novel Treatment's Market Potential and Financial Upside
ATyr Pharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on ATyr Pharma, Maintains $35 Price Target
ATyr Pharma Analyst Ratings
RBC Capital Sticks to Their Buy Rating for ATyr Pharma (LIFE)
Strong Buy Rating for ATyr Pharma as Efzofitimod Shows Promise and Financial Stability
ATyr Pharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: ATyr Pharma (LIFE), Conmed (CNMD) and Ascendis Pharma (ASND)
Buy Rating Affirmed for ATyr Pharma as Lead Candidate Efzofitimod Advances in Clinical Trials With Solid Financial Footing
ATyr Pharma Analyst Ratings
ATyr Pharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: ATyr Pharma (LIFE), CVS Health (CVS) and Science 37 (SNCE)
ATyr Pharma (LIFE) Gets a Hold From Oppenheimer
Promising Potential of ATyr Pharma's Efzofitimod in Treating Rheumatoid Arthritis and Associated Lung Disease Underpins Buy Rating
RBC Capital Keeps Their Buy Rating on ATyr Pharma (LIFE)
ATyr Pharma (LIFE) Receives a Buy From Piper Sandler
No Data